[go: up one dir, main page]

WO2011103382A3 - Compositions and methods for inducing angiogenesis - Google Patents

Compositions and methods for inducing angiogenesis Download PDF

Info

Publication number
WO2011103382A3
WO2011103382A3 PCT/US2011/025374 US2011025374W WO2011103382A3 WO 2011103382 A3 WO2011103382 A3 WO 2011103382A3 US 2011025374 W US2011025374 W US 2011025374W WO 2011103382 A3 WO2011103382 A3 WO 2011103382A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
inducing angiogenesis
pharmaceutical compositions
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/025374
Other languages
French (fr)
Other versions
WO2011103382A2 (en
Inventor
Shiladitya Sengupta
Ermanno Gherardi
Rituparana Sinha Roy
Shivani Soni
Rania Harfouche
Pooja R. Vasudevan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to CN2011800203513A priority Critical patent/CN103037892A/en
Publication of WO2011103382A2 publication Critical patent/WO2011103382A2/en
Publication of WO2011103382A3 publication Critical patent/WO2011103382A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to pharmaceutical compositions and to methods for inducing angiogenesis in conditions associated with insufficient vascularization, e.g. ischemia and diabetic conditions, such as diabetic foot ulcers. In particular, pharmaceutical compositions comprising sustained release nanoparticles that contain 1K1 fragment of Hepatocyte Growth Factor/Scatter Factor are provided.
PCT/US2011/025374 2010-02-22 2011-02-18 Compositions and methods for inducing angiogenesis Ceased WO2011103382A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011800203513A CN103037892A (en) 2010-02-22 2011-02-18 Compositions and methods for inducing angiogenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30676810P 2010-02-22 2010-02-22
US61/306,768 2010-02-22
US37896810P 2010-09-01 2010-09-01
US61/378,968 2010-09-01

Publications (2)

Publication Number Publication Date
WO2011103382A2 WO2011103382A2 (en) 2011-08-25
WO2011103382A3 true WO2011103382A3 (en) 2012-04-05

Family

ID=44483581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/025374 Ceased WO2011103382A2 (en) 2010-02-22 2011-02-18 Compositions and methods for inducing angiogenesis

Country Status (2)

Country Link
CN (1) CN103037892A (en)
WO (1) WO2011103382A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037521A1 (en) * 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
WO2014186075A2 (en) * 2013-05-15 2014-11-20 The Board Of Trustees Of The Leland Stanford Junior University Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing
PL3247719T3 (en) * 2015-01-21 2020-07-13 Université de Lille Met receptor agonist proteins
WO2022119563A1 (en) * 2020-12-02 2022-06-09 Shih Chun Che Composition and method for treatment of ischemic disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716450B1 (en) * 2000-05-18 2004-04-06 The United States Of America As Represented By The Secretary Of The Army Enhancing protein activity through nanoencapsulation
US20040234481A1 (en) * 2001-05-09 2004-11-25 Ryuichi Morishita Gene transfers of angiogenic factor for skin disease
US20080167224A1 (en) * 2001-04-27 2008-07-10 Medical Research Council Variants of the nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and their use
US20080213370A1 (en) * 1993-02-22 2008-09-04 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20090157046A1 (en) * 2007-11-09 2009-06-18 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101152151A (en) * 2007-08-31 2008-04-02 深圳市第二人民医院 A kind of vascular endothelial growth factor sustained-release microparticles and its preparation method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213370A1 (en) * 1993-02-22 2008-09-04 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6716450B1 (en) * 2000-05-18 2004-04-06 The United States Of America As Represented By The Secretary Of The Army Enhancing protein activity through nanoencapsulation
US20080167224A1 (en) * 2001-04-27 2008-07-10 Medical Research Council Variants of the nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and their use
US20040234481A1 (en) * 2001-05-09 2004-11-25 Ryuichi Morishita Gene transfers of angiogenic factor for skin disease
US20090157046A1 (en) * 2007-11-09 2009-06-18 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof

Also Published As

Publication number Publication date
WO2011103382A2 (en) 2011-08-25
CN103037892A (en) 2013-04-10

Similar Documents

Publication Publication Date Title
BR112012012108A2 (en) pharmaceutical composition comprising propofol
MX346224B (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
IL227625A0 (en) Nanoparticle compositions, formulations thereof, and uses therefor
DK2658525T3 (en) Biodegradable drug delivery composition
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EP2627317A4 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
LT3391890T (en) Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
IT1398316B1 (en) PIROETTING WHEEL STRUCTURE, PARTICULARLY FOR FURNITURE AND SIMILAR.
MX366090B (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
MX2013002422A (en) Salts of lorcaserin with optically active acids.
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
WO2012031164A3 (en) Drug delivery by carbon nanotube arrays
ZA201307593B (en) Antihypertensive pharmaceutical composition
PL2554168T3 (en) Controlled release pharmaceutical composition
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
WO2012040331A3 (en) Multistage nanoparticles
WO2011103382A3 (en) Compositions and methods for inducing angiogenesis
MX361407B (en) Hydrocortisone controlled release formulation.
MX344189B (en) Formulations of mazindol.
EP2490689A4 (en) Injectable formulations for intra- articular or peri-articular administration
EP2867990B8 (en) Quasi-broadband amplifier according to the doherty principle
EP2611799A4 (en) Pharmaceutical compositions of linezolid
CL2013001445A1 (en) Compounds derived from diphenylamine; Pharmaceutical composition and use in the treatment of inflammatory diseases, such as cancer.
MX356727B (en) Modified release formulations of viloxazine.
SMT201600243B (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANAKINRA WITHOUT CITRATE

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180020351.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11745291

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7712/DELNP/2012

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 11745291

Country of ref document: EP

Kind code of ref document: A2